Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of upadacitinib in non-segmental vitiligo
jRCT2031230663Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Vitiligo comparing Upadacitinib with Placebo (2 arms). Primary endpoints: Percentage of Participants Achieving T-VASI50 at Week 48 and Percentage of Participants Achieving F-VASI75 at Week 48. Started Dec 2023; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
Vitiligo
Beyond the preview
Go deeper on jRCT2031230663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230663.